The US Drug Enforcement Administration's (DEA’s) reluctance to approve regulations covering the electronic prescribing of controlled substances is costing the country billions in health care savings each year, said Sen Sheldon Whitehouse (D, RI). This heel dragging is also causing unnecessary adverse drug events, which occur more often with patients who receive their medications via a handwritten prescription, said Whitehouse, who chaired a December hearing on the issue by the Senate Judiciary Committee.
Mitka M. e-Prescribing Barrier. JAMA. 2008;299(6):625. doi:10.1001/jama.299.6.625-c
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: